NCI-CTCAE grades 3/4 potentially related adverse events in 5% or more of patients
| Adverse event . | Laromustine/HDAC, n = 177, no. (%) . | HDAC/placebo, n = 86, no. (%) . |
|---|---|---|
| Febrile neutropenia | 81 (46) | 42 (49) |
| Neutropenic infection | 15 (8) | 7 (8) |
| Pneumonia | 15 (8) | 4 (5) |
| Neutropenic sepsis | 11 (6) | 5 (6) |
| Bacteremia | 15 (8) | 4 (5) |
| Sepsis | 8 (5) | 2 (2) |
| Dyspnea | 26 (15) | 4 (5) |
| Hypoxia | 19 (11) | 2 (2) |
| Acute respiratory distress syndrome | 5 (3) | 0 |
| Pyrexia | 14 (8) | 4 (5) |
| Fatigue | 13 (7) | 1 (1) |
| Hypotension | 15 (9) | 4 (5) |
| Diarrhea | 12 (7) | 1 (1) |
| Hypokalemia | 25 (14) | 6 (7) |
| Hyperglycemia | 9 (5) | 5 (6) |
| Adverse event . | Laromustine/HDAC, n = 177, no. (%) . | HDAC/placebo, n = 86, no. (%) . |
|---|---|---|
| Febrile neutropenia | 81 (46) | 42 (49) |
| Neutropenic infection | 15 (8) | 7 (8) |
| Pneumonia | 15 (8) | 4 (5) |
| Neutropenic sepsis | 11 (6) | 5 (6) |
| Bacteremia | 15 (8) | 4 (5) |
| Sepsis | 8 (5) | 2 (2) |
| Dyspnea | 26 (15) | 4 (5) |
| Hypoxia | 19 (11) | 2 (2) |
| Acute respiratory distress syndrome | 5 (3) | 0 |
| Pyrexia | 14 (8) | 4 (5) |
| Fatigue | 13 (7) | 1 (1) |
| Hypotension | 15 (9) | 4 (5) |
| Diarrhea | 12 (7) | 1 (1) |
| Hypokalemia | 25 (14) | 6 (7) |
| Hyperglycemia | 9 (5) | 5 (6) |
NCI-CTCAE indicates National Cancer Institute Common Toxicity Criteria for Adverse Events.